Chroma Medicine, a genomic medicine company that focuses on developing single-dose epigenetic editing therapeutics, announced that it has raised $135 million in Series B funding led by GV (Google Ventures). The funding round also saw participation from other new investors including ARCH Venture Partners, DCVC Bio, Mubadala Capital, and Sixth Street, and all existing investors such as Alexandria Venture Investments, Atlas Venture, Casdin Capital, and others.
Chroma Medicine will use the funding to advance its therapeutic programs towards clinical development and to continue investing in its core epigenetic editing platform. The company’s single-dose epigenetic editors regulate gene expression without changing the underlying DNA sequence, which allows the company to address a wide range of diseases and target multiple pathways for complex diseases.
Chroma’s approach avoids the risks associated with traditional gene editing methods that cut or nick DNA, which can lead to unpredictable DNA repair pathways. Chroma’s single-dose epigenetic editing approach harnesses the cell’s innate mechanism for gene regulation to precisely and durably silence, activate, and multiplex genes using a single platform.
“Epigenetic editing is a promising new frontier for gene regulation,” said Issi Rozen, Venture Partner at GV. “Chroma’s technology enables durable modulation of gene expression, providing potentially transformative treatments for patients living with serious diseases.”
Catherine Stehman-Breen, M.D., CEO of Chroma Medicine, said, “We’re grateful to this exceptional syndicate of investors, whose commitment enables our ongoing drive to introduce this new class of precision genomic medicines with curative potential to patients with serious illnesses.”
Chroma Medicine is a biotechnology company that aims to harness epigenetics, nature’s innate mechanism for gene regulation, to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company’s founding team includes the world’s foremost experts in genomic research, and it is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development.
